Literature DB >> 17652061

Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.

M Santisteban1, Y Nieto, S De la Cruz, J Aristu, J L Zubieta, O Fernández Hidalgo.   

Abstract

We report a case of primary CNS lymphoma treated with high-dose methotrexate in the first line. After disease progression the patient received cranial radiotherapy with concomitant temozolomide, followed by rituximab plus temozolomide, with complete remission of the disease maintained for at least two years and without major toxicity.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17652061     DOI： 10.1007/s12094-007-0086-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  8 in total

Review 1.  Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

Authors:  Roelien H Enting; Alexis Demopoulos; Lisa M DeAngelis; Lauren E Abrey
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

2.  Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study.

Authors:  Christian Lotze; Frank Schüler; William H Krüger; Carsten Hirt; Michael Kirsch; Silke Vogelgesang; Christian A Schmidt; Gottfried Dölken
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

3.  In vitro evaluation of temozolomide combined with X-irradiation.

Authors:  S R Wedge; J K Porteous; M G Glaser; K Marcus; E S Newlands
Journal:  Anticancer Drugs       Date:  1997-01       Impact factor: 2.248

4.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Authors:  S Alas; C Emmanouilides; B Bonavida
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

5.  Treatment for primary CNS lymphoma: the next step.

Authors:  L E Abrey; J Yahalom; L M DeAngelis
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

6.  High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

Authors:  J Y Blay; T Conroy; C Chevreau; A Thyss; N Quesnel; H Eghbali; R Bouabdallah; B Coiffier; J P Wagner; A Le Mevel; D Dramais-Marcel; E Baumelou; F Chauvin; P Biron
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

7.  Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.

Authors:  Michele Reni; Warren Mason; Francesco Zaja; James Perry; Enrico Franceschi; Daniele Bernardi; Stefania Dell'Oro; Caterina Stelitano; Marco Candela; Antonio Abbadessa; Andrea Pace; Roberto Bordonaro; Giancarlo Latte; Eugenio Villa; Andrés J M Ferreri
Journal:  Eur J Cancer       Date:  2004-07       Impact factor: 9.162

8.  Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Authors:  Eric T Wong; Roy Tishler; Loretta Barron; Julian K Wu
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860
  8 in total
  5 in total

1.  Diffuse large B-cell lymphoma recurrence presenting as multiple, progressive cranial neuropathies.

Authors:  Abby R Goron; Stephen Devlin; Stacy Schwartz
Journal:  BMJ Case Rep       Date:  2019-07-19

Review 2.  Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation.

Authors:  Frank Lieberman; Victor Yazbeck; Anastasios Raptis; Raymond Felgar; Michael Boyiadzis
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

3.  Salvage therapy for refractory AIDS-related primary central nervous system lymphoma.

Authors:  Hugo Ferro; Eduardo Parino
Journal:  Case Rep Oncol Med       Date:  2012-09-18

4.  MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Kamraan Z Gill; Fabio Iwamoto; Ashleigh Allen; Daniela Hoehn; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

5.  A minimal physiologically based pharmacokinetic model for high-dose methotrexate.

Authors:  Giuseppe Pesenti; Marco Foppoli; Davide Manca
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-13       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.